Additional file 1: Table S1. of Long-term efficacy and safety of fingolimod in Japanese patients with relapsing multiple sclerosis: 3-year results of the phase 2 extension study

Duration of exposure to fingolimod in patients entering the extension study. Table S2. Plasma levels of liver enzymes at core study baseline and in the extension study. Table S3. Proportion of patients with normal and elevated levels of liver enzymes. Table S4. Proportion of patients with normal and decreased levels of hematological parameters. (DOCX 35 kb